Paradigm Medical Names Stephen Davis as President

SALT LAKE CITY--(BUSINESS WIRE)--The Board of Directors of Paradigm Medical Industries, Inc. (OTCBB: PMED) named Stephen L. Davis as President, effective November 18, 2008. He replaces Raymond Cannefax, who was terminated.

“He is an exceptional manager and strategist.”

Mr. Davis, who previously served as the Company’s Vice-President Sales and Marketing from May 2007 to February 2008, has more than 20 years experience in the ophthalmic industry.

“We believe Stephen Davis will be able to help expand the Company’s proprietary products and devices domestically and internationally,” said Paradigm Medical’s Board Chairman Randall Mackey. “He is an exceptional manager and strategist.”

Mr. Davis noted, “Short-term, my efforts will be to reinvigorate Paradigm Medical’s global sales and marketing efforts and ensure product availability to our customers. And we will continue to exercise strong financial management. Our product mix is unsurpassed in the ophthalmic industry and we will continue to meet the current and future needs of the market.

“Longer-term, my goal is to capitalize on our strengths, which will result in solid and sustainable growth for the Company and maximizing our returns,” Mr. Davis added.

From 2001-2007, Mr. Davis served as President of SL Davis Group, Inc., which provides business development, distribution management and sales training services. From 1991-1999, Mr. Davis was President and Chief Executive Officer for Zinetics Medical, Inc., which manufactured and distributed medical devices for the gastroenterology and critical care markets. He has held other senior management positions at Co-Care Medical Services, Inc., and Ioptex Intraocular Lenses, Inc.

Paradigm Medical Industries, Inc. is a leader in ultrasound devices, and glaucoma detection and management products.

This press release contains statement that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.